IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

CRISCITIELLO, CARMEN
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3629
NA - Nord America 3014
AS - Asia 1335
SA - Sud America 63
OC - Oceania 53
AF - Africa 19
Continente sconosciuto - Info sul continente non disponibili 8
Totale 8121
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2883
GB - Regno Unito 1833
CN - Cina 867
IT - Italia 597
SE - Svezia 452
IE - Irlanda 195
DE - Germania 166
JP - Giappone 120
FR - Francia 116
CA - Canada 105
IN - India 77
VN - Vietnam 54
ES - Italia 48
AU - Australia 46
TR - Turchia 45
NL - Olanda 39
KR - Corea 34
TW - Taiwan 33
DK - Danimarca 27
BR - Brasile 25
MX - Messico 24
ID - Indonesia 23
BE - Belgio 20
CH - Svizzera 17
RO - Romania 15
TH - Thailandia 15
UA - Ucraina 15
AR - Argentina 12
GR - Grecia 12
HK - Hong Kong 12
FI - Finlandia 11
PH - Filippine 11
RU - Federazione Russa 11
AT - Austria 10
CO - Colombia 10
IR - Iran 9
PL - Polonia 8
SG - Singapore 8
NO - Norvegia 7
NZ - Nuova Zelanda 7
AP - ???statistics.table.value.countryCode.AP??? 6
CL - Cile 6
KE - Kenya 6
PT - Portogallo 6
BY - Bielorussia 5
HR - Croazia 5
JO - Giordania 5
AE - Emirati Arabi Uniti 4
EC - Ecuador 4
SC - Seychelles 4
SK - Slovacchia (Repubblica Slovacca) 4
EG - Egitto 3
EU - Europa 3
IL - Israele 3
LB - Libano 3
PK - Pakistan 3
UY - Uruguay 3
ZA - Sudafrica 3
CU - Cuba 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
EE - Estonia 2
HU - Ungheria 2
MY - Malesia 2
SA - Arabia Saudita 2
AM - Armenia 1
BG - Bulgaria 1
CY - Cipro 1
FK - Isole Falkland (Malvinas) 1
IM - Isola di Man 1
IQ - Iraq 1
LT - Lituania 1
MA - Marocco 1
MO - Macao, regione amministrativa speciale della Cina 1
PE - Perù 1
RS - Serbia 1
SR - Suriname 1
UZ - Uzbekistan 1
Totale 8122
Salva come PNG Salva come JPEG
Città #
Southend 1769
Milan 337
Chandler 316
Fairfield 307
Houston 272
Dublin 191
Princeton 181
Wilmington 170
Ashburn 126
Woodbridge 118
Nanjing 117
Redwood City 110
Seattle 109
Guangzhou 107
Cambridge 105
Beijing 104
Ann Arbor 73
Des Moines 60
Dearborn 59
Shanghai 59
Toronto 56
Phoenix 42
Shenyang 41
Jinan 39
Boardman 37
Hangzhou 29
San Diego 29
Tokyo 27
Sunnyvale 26
Istanbul 25
Zhengzhou 25
Changsha 23
Hebei 23
Berlin 20
Grafing 20
Dong Ket 19
Seoul 18
Redmond 16
Taipei 16
Hanover 15
London 15
Nanchang 15
Tianjin 15
Silver Spring 14
Haikou 13
Madrid 13
Taiyuan 12
Ottawa 11
Wuhan 11
Kunming 10
Amsterdam 9
Boston 9
Brussels 9
Central District 9
Jiaxing 9
Chengdu 8
Fort Worth 8
Mountain View 8
San Giuliano Milanese 8
São Paulo 8
Taizhou 8
Bangkok 7
Nanning 7
Osaka 7
Sydney 7
Denver 6
Florence 6
Fremont 6
Fuzhou 6
Groningen 6
Hefei 6
Mexico City 6
Naples 6
New York 6
Québec 6
Turin 6
Andover 5
Bogotá 5
Changchun 5
Columbus 5
Gresham 5
Milwaukee 5
Montréal 5
Norwalk 5
Philadelphia 5
Rho 5
Richmond 5
Roxbury 5
San Jose 5
Upper Marlboro 5
Zaragoza 5
Atlanta 4
Barcelona 4
Birmingham 4
Bologna 4
Buffalo 4
Green Bay 4
Guangdong 4
Lanzhou 4
Los Angeles 4
Totale 5663
Salva come PNG Salva come JPEG
Nome #
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines 1345
Global cancer control: responding to the growing burden, rising costs and inequalities in access 725
Entinostat for the treatment of breast cancer 470
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials 211
Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple-negative breast cancer : a systematic review 185
Managing side effects of immune checkpoint inhibitors in breast cancer 162
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer 154
Expression of tumor-associated antigens in breast cancer subtypes 150
Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs 147
Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients : a Single-Institute Study 124
Antibody–drug conjugates in solid tumors: a look into novel targets 120
Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer 117
Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars : a physician survey in the united states and emerging markets 116
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer : a systematic review of randomized controlled trials 113
Immune approaches to the treatment of breast cancer, around the corner? 113
Immune checkpoint blockade in cancer treatment : a double-edged sword cross-targeting the host as an "innocent bystander" 108
Impact of autoimmune diseases on outcome of patients with early breast cancer 105
Biopsy confirmation of metastatic sites in breast cancer patients : clinical impact and future perspectives 105
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer : a retrospective multicenter study 105
RNAi screens identify CHD4 as an essential gene in breast cancer growth 103
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 101
Pten alterations and their role in cancer management: Are we making headway on precision medicine? 96
Immunotherapy in breast cancer patients: A focus on the use of the currently available biomarkers in oncology 91
Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: a randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine 90
Successes and limitations of targeted cancer therapy in breast cancer 89
Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date. 87
Cardiotoxicity of anticancer treatments : epidemiology, detection, and management 86
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials 82
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management 80
Immune checkpoint inhibitors with radiotherapy and locoregional treatment : synergism and potential clinical implications 79
Strategies to modulate the immune system in breast cancer : checkpoint inhibitors and beyond 75
Tumour dormancy and clinical implications in breast cancer 75
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors : a Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group : Part 1 : Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 72
Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer 72
WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells 71
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer 69
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer : results from Neo-ALTTO 69
Impact of Rehabilitation on Breast Cancer Related Fatigue : A Pilot Study 69
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis 68
Best management of locally advanced inoperable breast cancer 64
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer 63
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 61
Tumor-stroma crosstalk : targeting stroma in breast cancer 59
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer 58
Mechanism of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist 57
QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation : a comprehensive review 57
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer 57
HER2 signaling pathway and trastuzumab cardiotoxicity 57
Dinaciclib for the treatment of breast cancer 55
Locoregional recurrence in patients with HER2 positive breast cancer 54
Targeting fibroblast growth factor receptor pathway in breast cancer 53
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer 53
Breast conservation following neoadjuvant therapy for breast cancer in the modern era : are we losing the opportunity? 52
Dendritic cell-based vaccines : clinical applications in breast cancer 52
Highlights from the 13th St Gallen International Breast Cancer Conference 2013 : access to innovation for patients with breast cancer: How to speed it up? 52
Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy 51
The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations 51
Crosstalk between bone niche and immune system : osteoimmunology signaling as a potential target for cancer treatment 50
Monitoring tumor-derived cell-free DNA in patients with solid tumors : clinical perspectives and research opportunities 49
Pharmacological management of male breast cancer 49
No link between breast cancer and meningioma : results from a large monoinstitutional retrospective analysis 48
Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? 48
Neoadjuvant model for testing emerging targeted therapies in breast cancer 47
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials 47
Adjuvant treatment of early male breast cancer 46
HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence 44
Over-using chemotherapy in the adjuvant setting 43
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies 43
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 43
Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: A systematic review and meta-analysis of randomized clinical trials 43
Immunotherapy of Breast Cancer 42
Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer 41
Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer 41
Targeting the subtypes of breast cancer: Rethinking investigational drugs 40
Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer 40
Peptide vaccines in early breast cancer 38
Erratum: Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: A retrospective multicenter study [Ann Oncol, 25, (2015) 611-618] DOI: 10.1093/annonc/mdt556 36
Immunotherapeutics for breast cancer 36
Optimal adjuvant chemotherapy in breast cancer : selection of agents 36
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy 36
Molecular pathways : human leukocyte antigen G(HLA-G) 35
Liquid biopsies for solid tumors : understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies 35
Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial 35
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus 35
Developing an effective breast cancer vaccine : challenges to achieving sterile immunity versus resetting equilibrium 34
Impact of neoadjuvant chemotherapy and pathological complete response on eligibility for breast-conserving surgery in patients with early breast cancer: A meta-analysis 34
Benefit of adjuvant chemotherapy in patients with lobular breast cancer : A systematic review of the literature and metanalysis 34
Efficacy of Antiresorptive Drugs on Bone Mineral Density in Post-Menopausal Women With Early Breast Cancer Receiving Adjuvant Aromatase Inhibitors: A Systematic Review of Randomized Controlled Trials 27
Treatment in real-life patients with HER2-positive metastatic breast cancer: What we learn from the KAMILLA trial? 20
Evolution of low HER2 expression between early and advanced-stage breast cancer 20
Tumour infiltrating lymphocytes and correlation with response to intensified platinum-based chemotherapy in BRCA-like tumours 18
Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer 14
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 14
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 10
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer 10
Targeting brain metastases in breast cancer 8
Metaplastic breast cancer: an all-round multidisciplinary consensus 5
Totale 8679
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14363
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14363
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201843 0000 00 00 00043
2018/20191340 1766013668 7496 15969 119116133134
2019/20201830 194141111166 149265 165121 16317310082
2020/20211753 10911413089 267117 87137 196145173189
2021/20221406 1301209089 12990 13663 1919460214
2022/20231552 171144167150 123256 63121 193371189
Totale 8679